论文部分内容阅读
亚硝基脲类化合物作为肿瘤化学治疗的一类新的药物,近十年来通过广泛的研究,取得相当大的进展,其中双氯乙基亚硝基脲(BCNU、卡氮芥)、1-(2-氯乙基)-3-环己基-1-亚硝基脲(CCNU)、1-(2-氯乙基)-3-(4-甲基环己基)-1-亚硝基脲(甲基-CCNU)均已先后进入临床试验,并取得了一定的治疗效果。在国外BCNU已完成临床试验作为商品出售,CCNU已进入第二期确定临床疗效阶段,甲基-CCNU已完成第一期临床药理试验。据报道,美苏抗癌药物临床研究协定中,CCNU即为美向苏提供的三个抗癌药物之一,在苏联进行第二期临床研究。在国内BCNU的研究试制和临床试验业已完成,并通过技术鉴定正式投产,CCNU也已进入临
Nitrosourea compounds as a new class of chemotherapy drugs in the past decade, through extensive research and made considerable progress, of which dichloroethyl nitrosourea (BCNU, Carmustine), 1- (2-chloroethyl) -3-cyclohexyl-1- nitrosourea (CCNU), 1- (2-chloroethyl) -3- (4- methylcyclohexyl) (Methyl-CCNU) have entered the clinical trials, and achieved some therapeutic effect. BCNU in foreign countries have completed clinical trials as a commodity sale, CCNU has entered the second phase to determine the clinical efficacy of methyl-CCNU has completed the first phase of clinical pharmacology trials. It is reported that the United States and the Soviet Union in the clinical study of anti-cancer drugs agreement, CCNU is the United States to the Soviet Union to provide one of the three anti-cancer drugs in the Soviet Union for the second phase of clinical studies. In the domestic BCNU trial trial and clinical trials have been completed and formally put into operation through technical appraisal, CCNU has entered the Pro